{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T12:19:48Z","timestamp":1787141988551,"version":"build-2736575974"},"reference-count":26,"publisher":"American Society of Hematology","issue":"1","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,1,13]]},"abstract":"<jats:sec>\n                    <jats:title>Abstract<\/jats:title>\n                    <jats:p>Classical Hodgkin lymphoma (CHL) is characterized by a complex tumor microenvironment (TME) that supports disease progression. Although immune cell recruitment by Hodgkin and Reed-Sternberg (HRS) cells is well documented, the role of nonmalignant B cells in relapse remains unclear. Using single-cell RNA sequencing (scRNA-seq) on paired diagnostic and relapsed CHL samples, we identified distinct shifts in B-cell populations, particularly an enrichment of na\u00efve B cells and a reduction of memory B cells in early-relapse CHL compared to late-relapse and newly diagnosed CHL. The enrichment of na\u00efve B cells in early relapse biopsies was confirmed in independent validation cohorts using scRNA-seq and immunohistochemistry. Notably, na\u00efve B cells in early-relapse samples exhibited high expression of LGALS9, an immunosuppressive gene encoding galectin-9, which binds to HAVCR2 (T-cell immunoglobulin and mucin domain\u2013containing protein 3 [TIM-3]) on regulatory T cells (Tregs). Cell-cell interaction analysis revealed the importance of interactions between LGALS9+ na\u00efve B cells and HAVCR2+ Tregs in the early-relapse setting. Spatial analysis by imaging mass cytometry confirmed close proximity of galectin-9\u2013positive na\u00efve B cells with TIM-3+ CD4+ T cells and HRS cells, pointing to their role in shaping an immunosuppressive niche. Our findings highlight a previously unrecognized population of galectin-9\u2013positive na\u00efve B cells with immunoregulatory potential in early-relapse CHL and provide new insights into the spatial and transcriptional architecture of the relapsed TME in CHL.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1182\/bloodadvances.2025017107","type":"journal-article","created":{"date-parts":[[2025,9,9]],"date-time":"2025-09-09T19:08:46Z","timestamp":1757444926000},"page":"29-38","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":3,"title":["Tumor microenvironment differences between diagnostic and relapsed classic Hodgkin lymphoma revealed by scRNA-seq"],"prefix":"10.1182","volume":"10","author":[{"given":"Yifan","family":"Yin","sequence":"first","affiliation":[{"name":"1Centre for Lymphoid Cancer, BC Cancer, Vancouver, BC, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinya","family":"Rai","sequence":"additional","affiliation":[{"name":"1Centre for Lymphoid Cancer, BC Cancer, Vancouver, BC, Canada"},{"name":"2Department of Hematology and Rheumatology, Faculty of Medicine, Kindai University, Osaka-Sayama, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6153-7595","authenticated-orcid":false,"given":"Aixiang","family":"Jiang","sequence":"additional","affiliation":[{"name":"1Centre for Lymphoid Cancer, BC Cancer, Vancouver, BC, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4877-4358","authenticated-orcid":false,"given":"Alexander","family":"Xu","sequence":"additional","affiliation":[{"name":"3Department of Bioengineering, University of Maryland, College Park, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luke","family":"O\u2019Brien","sequence":"additional","affiliation":[{"name":"1Centre for Lymphoid Cancer, BC Cancer, Vancouver, BC, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ad\u00e8le","family":"Telenius","sequence":"additional","affiliation":[{"name":"1Centre for Lymphoid Cancer, BC Cancer, Vancouver, BC, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5023-0689","authenticated-orcid":false,"given":"Jan","family":"Delabie","sequence":"additional","affiliation":[{"name":"4Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lauren","family":"Chong","sequence":"additional","affiliation":[{"name":"1Centre for Lymphoid Cancer, BC Cancer, Vancouver, BC, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stacy","family":"Hung","sequence":"additional","affiliation":[{"name":"1Centre for Lymphoid Cancer, BC Cancer, Vancouver, BC, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7472-822X","authenticated-orcid":false,"given":"Akil","family":"Merchant","sequence":"additional","affiliation":[{"name":"5Cedars-Sinai Medical Center, Los Angeles, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0435-5947","authenticated-orcid":false,"given":"David W.","family":"Scott","sequence":"additional","affiliation":[{"name":"1Centre for Lymphoid Cancer, BC Cancer, Vancouver, BC, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5835-9863","authenticated-orcid":false,"given":"Kerry J.","family":"Savage","sequence":"additional","affiliation":[{"name":"1Centre for Lymphoid Cancer, BC Cancer, Vancouver, BC, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6782-8361","authenticated-orcid":false,"given":"Tomohiro","family":"Aoki","sequence":"additional","affiliation":[{"name":"4Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9842-9750","authenticated-orcid":false,"given":"Christian","family":"Steidl","sequence":"additional","affiliation":[{"name":"1Centre for Lymphoid Cancer, BC Cancer, Vancouver, BC, Canada"},{"name":"6Department of Pathology and Laboratory Medicine, The University of British Columbia, Vancouver, BC, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2025,12,29]]},"reference":[{"issue":"15","key":"2026011309013753200_bib1","doi-asserted-by":"crossref","first-page":"1791","DOI":"10.1182\/blood.2022017147","article-title":"Novel insights into Hodgkin lymphoma biology by single-cell analysis","volume":"141","author":"Aoki","year":"2023","journal-title":"Blood"},{"issue":"8","key":"2026011309013753200_bib2","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1038\/nrc3774","article-title":"The tumour microenvironment in B cell lymphomas","volume":"14","author":"Scott","year":"2014","journal-title":"Nat Rev Cancer"},{"key":"2026011309013753200_bib3","doi-asserted-by":"publisher","DOI":"10.1200\/JCO-25-00204","article-title":"Nivolumab-AVD versus brentuximab vedotin-AVD in older patients with advanced-stage classic Hodgkin lymphoma enrolled on S1826","author":"Rutherford","year":"16  2025","journal-title":"J Clin Oncol"},{"issue":"15","key":"2026011309013753200_bib4","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1056\/NEJMoa2405888","article-title":"Nivolumab+AVD in advanced-stage classic Hodgkin's lymphoma","volume":"391","author":"Herrera","year":"2024","journal-title":"N Engl J Med"},{"issue":"4","key":"2026011309013753200_bib5","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1056\/NEJMoa2206125","article-title":"Overall survival with brentuximab vedotin in stage III or IV Hodgkin's lymphoma","volume":"387","author":"Ansell","year":"2022","journal-title":"N Engl J Med"},{"issue":"26","key":"2026011309013753200_bib6","doi-asserted-by":"crossref","first-page":"6400","DOI":"10.1200\/JCO.2005.05.016","article-title":"State-of-the-art therapeutics: Hodgkin's lymphoma","volume":"23","author":"Connors","year":"2005","journal-title":"J Clin Oncol"},{"issue":"2","key":"2026011309013753200_bib7","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1007\/s00277-019-03900-x","article-title":"Outcome after autologous stem cell transplantation in primary refractory or relapsed Hodgkin lymphoma-a long-term follow-up single center experience","volume":"99","author":"Roerden","year":"2020","journal-title":"Ann Hematol"},{"issue":"22","key":"2026011309013753200_bib8","doi-asserted-by":"crossref","first-page":"2420","DOI":"10.1182\/blood-2017-03-770719","article-title":"Topological analysis reveals a PD-L1-associated microenvironmental niche for Reed-Sternberg cells in Hodgkin lymphoma","volume":"130","author":"Carey","year":"2017","journal-title":"Blood"},{"issue":"7","key":"2026011309013753200_bib9","doi-asserted-by":"crossref","first-page":"794","DOI":"10.3324\/haematol.2015.132761","article-title":"The immune microenvironment in Hodgkin lymphoma: T cells, B cells, and immune checkpoints","volume":"101","author":"Vardhana","year":"2016","journal-title":"Haematologica"},{"issue":"10","key":"2026011309013753200_bib10","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1056\/NEJMoa0905680","article-title":"Tumor-associated macrophages and survival in classic Hodgkin's lymphoma","volume":"362","author":"Steidl","year":"2010","journal-title":"N Engl J Med"},{"issue":"5","key":"2026011309013753200_bib11","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.3390\/cancers14051360","article-title":"The Hodgkin lymphoma immune microenvironment: turning bad news into good","volume":"14","author":"Men\u00e9ndez","year":"2022","journal-title":"Cancers (Basel)"},{"issue":"2","key":"2026011309013753200_bib12","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1200\/JCO.2011.39.9881","article-title":"Expression of FOXP3, CD68, and CD20 at diagnosis in the microenvironment of classical Hodgkin lymphoma is predictive of outcome","volume":"31","author":"Greaves","year":"2013","journal-title":"J Clin Oncol"},{"issue":"14","key":"2026011309013753200_bib13","doi-asserted-by":"crossref","first-page":"1812","DOI":"10.1200\/JCO.2010.32.8401","article-title":"Molecular pathogenesis of Hodgkin's lymphoma: increasing evidence of the importance of the microenvironment","volume":"29","author":"Steidl","year":"2011","journal-title":"J Clin Oncol"},{"issue":"21","key":"2026011309013753200_bib14","doi-asserted-by":"crossref","first-page":"5503","DOI":"10.3390\/ijms20215503","article-title":"Immune and inflammatory cells of the tumor microenvironment represent novel therapeutic targets in classical Hodgkin lymphoma","volume":"20","author":"Calabretta","year":"2019","journal-title":"Int J Mol Sci"},{"issue":"12","key":"2026011309013753200_bib15","doi-asserted-by":"crossref","first-page":"2765","DOI":"10.1182\/blood-2008-07-168096","article-title":"Molecular profiling of classical Hodgkin lymphoma tissues uncovers variations in the tumor microenvironment and correlations with EBV infection and outcome","volume":"113","author":"Chetaille","year":"2009","journal-title":"Blood"},{"issue":"9","key":"2026011309013753200_bib16","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1200\/JCO.23.01115","article-title":"Spatially resolved tumor microenvironment predicts treatment outcomes in relapsed\/refractory Hodgkin lymphoma","volume":"42","author":"Aoki","year":"2024","journal-title":"J Clin Oncol"},{"issue":"12","key":"2026011309013753200_bib17","doi-asserted-by":"crossref","first-page":"1878","DOI":"10.1038\/s41591-020-1061-7","article-title":"Characteristics of anti-CD19 CAR T cell infusion products associated with efficacy and toxicity in patients with large B cell lymphomas","volume":"26","author":"Deng","year":"2020","journal-title":"Nat Med"},{"issue":"13","key":"2026011309013753200_bib18","doi-asserted-by":"crossref","first-page":"3573","DOI":"10.1016\/j.cell.2021.04.048","article-title":"Integrated analysis of multimodal single-cell data","volume":"184","author":"Hao","year":"2021","journal-title":"Cell"},{"issue":"6","key":"2026011309013753200_bib19","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1038\/s41587-019-0113-3","article-title":"Efficient integration of heterogeneous single-cell transcriptomes using Scanorama","volume":"37","author":"Hie","year":"2019","journal-title":"Nat Biotechnol"},{"issue":"1","key":"2026011309013753200_bib20","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1038\/s41467-021-21246-9","article-title":"Inference and analysis of cell-cell communication using CellChat","volume":"12","author":"Jin","year":"2021","journal-title":"Nat Commun"},{"issue":"3","key":"2026011309013753200_bib21","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1158\/2159-8290.CD-19-0680","article-title":"Single-cell transcriptome analysis reveals disease-defining T-cell subsets in the tumor microenvironment of classic Hodgkin lymphoma","volume":"10","author":"Aoki","year":"2020","journal-title":"Cancer Discov"},{"key":"2026011309013753200_bib22","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.canlet.2021.04.011","article-title":"The TIM3\/Gal9 signaling pathway: an emerging target for cancer immunotherapy","volume":"510","author":"Kandel","year":"2021","journal-title":"Cancer Lett"},{"key":"2026011309013753200_bib23","doi-asserted-by":"crossref","first-page":"580557","DOI":"10.3389\/fimmu.2020.580557","article-title":"Ligand-receptor interactions of galectin-9 and VISTA suppress human T lymphocyte cytotoxic activity","volume":"11","author":"Yasinska","year":"2020","journal-title":"Front Immunol"},{"issue":"6","key":"2026011309013753200_bib24","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1158\/2326-6066.CIR-14-0072","article-title":"VISTA is a novel broad-spectrum negative checkpoint regulator for cancer immunotherapy","volume":"2","author":"Lines","year":"2014","journal-title":"Cancer Immunol Res"},{"issue":"1","key":"2026011309013753200_bib25","doi-asserted-by":"crossref","first-page":"3287","DOI":"10.1038\/s41467-018-05770-9","article-title":"Galectin-9 suppresses B cell receptor signaling and is regulated by I-branching of N-glycans","volume":"9","author":"Giovannone","year":"2018","journal-title":"Nat Commun"},{"issue":"1","key":"2026011309013753200_bib26","doi-asserted-by":"crossref","first-page":"3288","DOI":"10.1038\/s41467-018-05771-8","article-title":"Galectin-9 binds IgM-BCR to regulate B cell signaling","volume":"9","author":"Cao","year":"2018","journal-title":"Nat Commun"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/10\/1\/29\/2478179\/blooda_adv-2025-017107-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/10\/1\/29\/2478179\/blooda_adv-2025-017107-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,13]],"date-time":"2026-01-13T14:01:44Z","timestamp":1768312904000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/10\/1\/29\/547197\/Tumor-microenvironment-differences-between"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,29]]},"references-count":26,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1,13]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2025017107","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,1,13]]},"published":{"date-parts":[[2025,12,29]]}}}